Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study
Top Cited Papers
- 9 February 2017
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (5), 506-+
- https://doi.org/10.1200/JCO.2016.68.5826
Abstract
Purpose Cancer-related cognitive impairment is an important problem for patients with breast cancer, yet its trajectory is not fully understood. Some previous cancer-related cognitive impairment research is limited by heterogeneous populations, small samples, lack of prechemotherapy and longitudinal assessments, use of normative data, and lack of generalizability. We addressed these limitations in a large prospective, longitudinal, nationwide study. Patients and Methods Patients with breast cancer from community oncology clinics and age-matched noncancer controls completed the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) at prechemotherapy and postchemotherapy and at a 6-month follow-up as an a priori exploratory aim. Longitudinal models compared FACT-Cog scores between patients and controls at the three assessments and adjusted for age, education, race, menopausal status, and baseline reading ability, anxiety, and depressive symptoms. A minimal clinically important difference cutoff determined percentages of impairment over time. Results Of patients, 581 patients with breast cancer (mean age, 53 years; 48% anthracycline-based regimens) and 364 controls (mean age, 53 years) were assessed. Patients reported significantly greater cognitive difficulties on the FACT-Cog total score and four subscales from prechemotherapy to postchemotherapy compared with controls as well as from prechemotherapy to 6-month follow-up (all P< .001). Increased baseline anxiety, depression, and decreased cognitive reserve were significantly associated with lower FACT-Cog total scores. Treatment regimen, hormone, or radiation therapy was not significantly associated with FACT-Cog total scores in patients from postchemotherapy to 6-month follow-up. Patients were more likely to report a clinically significant decline in self-reported cognitive function than were controls from prechemotherapy to postchemotherapy (45.2% v 10.4%) and from prechemotherapy to 6-month follow-up (36.5% v 13.6%). Conclusion Patients with breast cancer who were treated in community oncology clinics report substantially more cognitive difficulties up to 6 months after treatment with chemotherapy than do age-matched noncancer controls. (C) 2016 by American Society of Clinical OncologyKeywords
This publication has 26 references indexed in Scilit:
- Functional brain connectivity and cognition: effects of adult age and task demandsNeurobiology of Aging, 2013
- Examining the influence of gender, education, social class and birth cohort on MMSE tracking over time: a population-based prospective cohort studyBMC Geriatrics, 2012
- Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment researchSupportive Care in Cancer, 2011
- Longitudinal Assessment of Cognitive Changes Associated With Adjuvant Treatment for Breast Cancer: Impact of Age and Cognitive ReserveJournal of Clinical Oncology, 2010
- Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic studyHeart, 2010
- Cognitive and Psychological Factors Associated with Early Posttreatment Functional Outcomes in Breast Cancer SurvivorsJournal of Psychosocial Oncology, 2009
- Evaluation of the Functional Assessment of Cancer Therapy Cognitive Scale with Hematopoetic Stem Cell Transplant PatientsJournal of Pain and Symptom Management, 2007
- Adriamycin-induced, TNF-α-mediated central nervous system toxicityNeurobiology of Disease, 2006
- Short-term effects of breast cancer on labor market attachment: results from a longitudinal studyJournal of Health Economics, 2005
- The cognitive sequelae of standard‐dose adjuvant chemotherapy in women with breast carcinomaCancer, 2004